Clinical Trial Update: A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products [Phase 3]

View source ↗

Summary

A Phase III trial update evaluating transition from DRL Rituximab to a reference product in rheumatoid arthritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Dr. Reddy's Laboratories Limited | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2023-11-18